Form 4: Vaxcyte COO Jim Wassil Reports Share Transactions

Vaxcyte's Chief Operating Officer, Jim Wassil, reported the disposition of shares for tax obligations and a transfer related to a divorce settlement, alongside an acquisition through an employee stock plan.

Summary

• Jim Wassil, Chief Operating Officer of Vaxcyte, Inc. (PCVX), reported several transactions involving the company's common stock.
• On September 2, 2025, Mr. Wassil disposed of a total of 4,286 shares of common stock at a price of $31.56 per share. These shares were surrendered to Vaxcyte to cover tax withholding obligations upon the vesting of Restricted Stock Units (RSUs).
• Prior to these transactions, on April 1, 2025, Mr. Wassil transferred 1,689 shares of Vaxcyte, Inc. Common Stock to his ex-spouse as part of a divorce settlement agreement.
• The reported beneficial ownership also includes 329 shares acquired under the Issuer's Employee Stock Purchase Plan on May 16, 2025.
• Following the reported transactions, Mr. Wassil's direct beneficial ownership stands at 146,270 shares of common stock.

Sentiment

Score: 5

Explanation: The filing reports routine insider transactions, including tax-related dispositions and a personal transfer, balanced by an ESPP acquisition. It does not indicate any significant positive or negative operational news for the company.

Positives

• Acquisition of 329 shares under the Employee Stock Purchase Plan on May 16, 2025, indicating continued participation in company equity programs.

Negatives

• Disposition of 4,286 shares to cover tax withholding obligations, which reduces direct beneficial ownership.
• Transfer of 1,689 shares to an ex-spouse due to a divorce settlement, further reducing personal beneficial ownership.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: Minor impact due to routine insider transactions. The reduction in direct beneficial ownership from tax withholdings and divorce is offset by the ESPP acquisition, and these are not indicative of management's view on the company's future performance.
• Employees: The ESPP acquisition highlights an ongoing employee benefit program.

Key Dates

Recommendation

This Form 4 filing details routine insider transactions, including share dispositions for tax obligations upon RSU vesting and a personal transfer due to a divorce settlement, alongside a minor acquisition via an employee stock purchase plan. These transactions are not indicative of a change in the company's fundamental performance or outlook. As such, the filing provides no new information to warrant a change in investment thesis, leading to a 'hold' recommendation.

Keywords

Vaxcyte, PCVX, Jim Wassil, Chief Operating Officer, Insider Trading, Form 4, Stock Transactions, RSU Vesting, Tax Withholding, Employee Stock Purchase Plan, Divorce Settlement, Share Disposition, Beneficial Ownership